Gabapentin Capsule
Product Images NDC 71205-671

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71205-671). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-671-72 (Gabapentin 400mg 30s)

Label for Gabapentin 400 mg capsules by Proficient Rx LP. The label indicates a package count of 120 capsules and includes details such as the NDC number 71205-671-72, manufacturer SciGen Pharmaceuticals, and storage instructions at 20-25°C. Capsules are described as size '0' hard gelatin with opaque orange caps and bodies, printed with 'SG' and '181' in black ink.*

FDA Label Image

Figure 1 (Image 01)

A line graph showing mean pain scores over an 8-week period comparing placebo and Gabapentin at 3600 mg/day. The x-axis represents weeks with baseline and weekly intervals, and the y-axis shows mean pain scores from 0 to 10. Gabapentin demonstrates a decreasing pain score trend over time, with a 4-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Figure 2 (Image 02)

A line graph depicting mean pain scores over a 7-week period comparing placebo with gabapentin at doses of 1800 mg/day and 2400 mg/day. The x-axis represents weeks including baseline, with a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores ranging from 0 to 10. Gabapentin groups show greater reduction in mean pain scores than placebo over time.*

FDA Label Image

Figure 3 (Image 03)

A bar chart titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It compares the proportion of responders in two studies between placebo (PBO) and different doses of gabapentin (GBP), showing increased response percentages with GBP doses ranging from 29% to 34% compared to placebo responses of 12% and 14%. Statistical significance is indicated with p-values < 0.01 and < 0.001.*

FDA Label Image

Cockcroft And Gault Equation (Image 04)

An illustration of a medical formula showing the calculation for creatinine clearance (CLCr). The formula includes variables for age in years, weight in kilograms, serum creatinine in mg/dL, and a factor of 0.85 for female patients.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of gabapentin showing a cyclohexane ring attached to aminomethyl and acetic acid functional groups. The image depicts the molecular arrangement of gabapentin, an active ingredient in the medication gabapentin 400 mg capsules.*

FDA Label Image

Image-09 (Image 09)

A scatter plot chart showing the percentage difference on the vertical axis versus daily dose in milligrams on the horizontal axis, with data points from three studies labeled as Study a, Study b, and Study c. The chart depicts differences at doses of approximately 600, 900, 1200, and 1800 mg, with Study a, b, and c represented by different square markers in black, gray, and white respectively.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.